LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

39.63 0.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

39.54

Максимум

40.16

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Марж на печалбата	-1,582.642
Служители	205
EBITDA	-6.8M -79M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+17.55% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.9B 6B
Предишно отваряне	39.55
Предишно затваряне	39.63

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.12.2025 г., 21:41 ч. UTC

Придобивния, сливания и поглъщания

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24.12.2025 г., 14:57 ч. UTC

Придобивния, сливания и поглъщания

Accenture to Acquire Cabel Industry from Fibonacci Group

25.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25.12.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25.12.2025 г., 00:20 ч. UTC

Придобивния, сливания и поглъщания

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24.12.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24.12.2025 г., 19:35 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.12.2025 г., 19:35 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of Christmas -- Market Talk

24.12.2025 г., 19:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

24.12.2025 г., 19:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24.12.2025 г., 19:06 ч. UTC

Пазарно говорене

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24.12.2025 г., 19:03 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

24.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.12.2025 г., 17:08 ч. UTC

Придобивния, сливания и поглъщания

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24.12.2025 г., 16:53 ч. UTC

Придобивния, сливания и поглъщания

Nike Climb Boosts Dow, S&P 500 -- WSJ

24.12.2025 г., 16:31 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24.12.2025 г., 16:28 ч. UTC

Придобивния, сливания и поглъщания

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24.12.2025 г., 16:17 ч. UTC

Пазарно говорене

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24.12.2025 г., 15:33 ч. UTC

Придобивния, сливания и поглъщания

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24.12.2025 г., 15:30 ч. UTC

Придобивния, сливания и поглъщания

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24.12.2025 г., 15:19 ч. UTC

Придобивния, сливания и поглъщания

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24.12.2025 г., 14:49 ч. UTC

Придобивния, сливания и поглъщания

Mexico's Ollamani Sells Stake in Azteca Stadium

24.12.2025 г., 14:19 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24.12.2025 г., 14:08 ч. UTC

Придобивния, сливания и поглъщания

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24.12.2025 г., 14:06 ч. UTC

Пазарно говорене

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24.12.2025 г., 13:24 ч. UTC

Пазарно говорене

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24.12.2025 г., 12:59 ч. UTC

Придобивния, сливания и поглъщания

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24.12.2025 г., 12:51 ч. UTC

Придобивния, сливания и поглъщания

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

17.55% нагоре

12-месечна прогноза

Среден 47.22 USD 17.55%

Висок 67 USD

Нисък 34 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.